Latest & greatest articles for diltiazem

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diltiazem or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diltiazem and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diltiazem

1. Metoprolol vs Diltiazem for atrial fibrillation

Metoprolol vs Diltiazem for atrial fibrillation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

2. Diltiazem

Diltiazem Top results for diltiazem - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for diltiazem The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Topical Minoxidil Versus Topical Diltiazem for Chemical Sphincterotomy of Chronic Anal Fissure: A Prospective, Randomized, Double-Blind, Clinical Trial

Topical Minoxidil Versus Topical Diltiazem for Chemical Sphincterotomy of Chronic Anal Fissure: A Prospective, Randomized, Double-Blind, Clinical Trial Anal fissure is a common anorectal problem causing severe pain and discomfort to the patients. Chemical sphincterotomy has emerged as a noninvasive alternative to the surgical methods of fissure treatment. The objective of this study was evaluation of the efficacy and the adverse effects of topically applied minoxidil in chemical sphincterotomy (...) of chronic anal fissure in comparison with topical diltiazem.A total of 88 patients with chronic anal fissure aged between 15 and 65 years were included in this double-blind, randomized clinical trial and were randomly assigned to either 0.5% minoxidil cream or 2% diltiazem cream twice daily for 2 weeks. The pain intensity, bleeding, wound healing, itching, headache, dizziness, significant drop in blood pressure, allergy and fissure relapse were assessed on a monthly basis for 2 months.Both diltiazem

2018 EvidenceUpdates

4. Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure

Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure Systematic review of the use of topical diltiazem compared with glyceryltrinitrate for the nonoperative management of chronic anal fissure Sajid MS, Whitehouse PA, Sains P, Baig MK CRD summary The review concluded (...) that diltiazem and glyceryl trinitrate were equally effective in the initial healing of chronic anal fissure but diltiazem should be the preferred first line of treatment due to a lower incidence of headache and recurrent fissure. Notwithstanding some review limitations, these conclusions appear reasonable and the call for a further trial seems appropriate. Authors' objectives To compare diltiazem with glyceryl trinitrate for the non-surgical management of chronic anal fissure. Searching Cochrane Colorectal

2013 DARE.

5. Chronic anal fissure: 2% topical diltiazem hydrochloride

Chronic anal fissure: 2% topical diltiazem hydrochloride Chronic anal fissure: 2% topical diltiazem Chronic anal fissure: 2% topical diltiazem h hy ydrochloride drochloride Evidence summary Published: 22 January 2013 nice.org.uk/guidance/esuom3 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc (...) ) or the MHRA or NICE websites for up-to-date information. Diltiazem hydrochloride is a calcium channel blocker and vasodilator. It increases blood flow to smooth muscles and relaxes muscle tone. Oral preparations of diltiazem hydrochloride are licensed in the UK to treat angina and hypertension. T opical diltiazem hydrochloride is not licensed in the UK for treating chronic anal fissure or any other indication. Therefore, its use for treating chronic anal fissure is unlicensed. An alternative topical

2013 National Institute for Health and Clinical Excellence - Advice

6. Simvastatin: dose limitations with concomitant amlodipine or diltiazem

Simvastatin: dose limitations with concomitant amlodipine or diltiazem Simvastatin: dose limitations with concomitant amlodipine or diltiazem - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Simvastatin: dose limitations with concomitant amlodipine or diltiazem The maximum recommended dose for simvastatin in conjunction with amlodipine and diltiazem is now 20 mg/day. Published 11 December 2014 From: Therapeutic area: , Contents Article date: October 2012 Pharmacokinetic data (...) Simvastatin is metabolised through the CYP3A4 pathway. Concomitant use of CYP3A4 inhibitors has the potential to increase exposure to simvastatin . Both amlodipine and diltiazem are substrates and inhibitors of CYP3A4 and therefore increase the plasma concentration (AUC0-24h) and maximum plasma concentration (Cmax) of simvastatin when they are co-administered. Studies have found that after 10 days of amlodipine (10 mg), the AUC0-24h of simvastatin and simvastatic acid following a single dose

2012 MHRA Drug Safety Update

7. Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure

Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure BestBets: Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure Intravenous diltiazem for the control of ventricular rate in patients with recent onset atrial fibrillation and left ventricular failure Report By: Dr Richard Parris - Consultant in Emergency Medicine Search checked (...) by Dr Simon Clarke - Consultant in Emergency Medicine, Frimley Park Hospital, Camberley, UK Institution: Royal Bolton Hospital, Lancs Date Submitted: 12th January 2005 Date Completed: 11th August 2009 Last Modified: 11th August 2009 Status: Green (complete) Three Part Question In a patient with [recent onset atrial fibrillation and left ventricular failure], can [diltiazem] [control the ventricular rate without worsening left ventricular function]? Clinical Scenario A 72-year-old woman with a past

2009 BestBETS

8. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation (PubMed)

Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation To compare the clinical efficacy of intravenous diltiazem, digoxin, and amiodarone for acute ventricular rate (VR) control in patients with acute symptomatic atrial fibrillation (AF) necessitating hospitalization.Randomized control trial.Acute emergency medical admission unit in a regional teaching hospital in Hong Kong.One (...) hundred fifty adult patients with acute AF and rapid VR (>120 bpm).Patients were randomly assigned in 1:1:1 ratio to receive intravenous diltiazem, digoxin, or amiodarone for VR control.The primary end point was sustained VR control (<90 bpm) within 24 hours; the secondary end points included AF symptom improvement and length of hospitalization. At 24 hours, VR control was achieved in 119 of 150 patients (79%). The time to VR control was significantly shorter among patients in the diltiazem group (log

2009 EvidenceUpdates

9. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. (Full text)

Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. Many patients with chronic angina experience anginal episodes despite revascularization and antianginal medications. In a previous trial, antianginal monotherapy with ranolazine, a drug believed to partially inhibit fatty acid oxidation, increased treadmill exercise performance; however, its long-term efficacy and safety (...) have not been studied in combination with beta-blockers or calcium antagonists in a large patient population with severe chronic angina.To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect

2004 JAMA PubMed

10. Diltiazem use in tacrolimus-treated renal transplant recipients

Diltiazem use in tacrolimus-treated renal transplant recipients Diltiazem use in tacrolimus-treated renal transplant recipients Diltiazem use in tacrolimus-treated renal transplant recipients Kothari J, Nash M, Zaltzman J, Prasad G V R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology The effects of using diltiazem as a first-line antihypertensive agent in renal transplant patients who received tacrolimus-based immunosuppressive treatment were evaluated. The mean average daily dose of diltiazem was 213.95 mg/day. Type of intervention Other: Management care (post-transplant). Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who underwent renal transplantation. Of those

2004 NHS Economic Evaluation Database.

11. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin

Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin Kumana C R, Tong M K, Li C S, Lauder I J, Lee J S, Kou M, Walley T, Haycox A, Chan T M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diltiazem, an antihypertensive agent, was used as a co-treatment to reduce the use of cyclosporin (i.e. Neoral) in renal transplant recipients. Neoral was a relatively new microemulsified cyclosporin formulation. Diltiazem was administered at a dose of 30 mg twice daily in patients weighing less than 60 kg, and at 60 mg twice daily

2003 NHS Economic Evaluation Database.

12. Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting

Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary (...) fibrillation (AF) in patients who had undergone coronary artery bypass grafting (CABG) was examined. The pathway was based on the administration of oral amiodarone, rate and rhythm control, cardioversion, and anticoagulation. Rate control, if needed, was mainly achieved with intravenous diltiazem and less often with a beta-blocker. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who had CABG

2002 NHS Economic Evaluation Database.

13. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. (PubMed)

Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Tardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has been

2000 Cochrane

14. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) (PubMed)

Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) Diltiazem reduces non-fatal reinfarction and refractory ischaemia after non-Q-wave myocardial infarction, an acute coronary syndrome similar to the incomplete infarction that occurs after successful reperfusion. We postulated that this agent would reduce cardiac events (...) in patients after acute myocardial infarction treated initially with thrombolytic agents-a clinical application previously unexplored with heart-rate-lowering calcium antagonists.A prospective, randomised, double-blind, sequential trial was done in 874 patients with acute myocardial infarction, but without congestive heart failure, who first received thrombolytic agents. Patients received either 300 mg oral diltiazem once daily, or placebo, initiated within 36-96 h of infarct onset, and given for up to 6

2000 Lancet

15. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. (PubMed)

Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Calcium antagonists are a first-line treatment for hypertension. The effectiveness of diltiazem, a non-dihydropyridine calcium antagonist, in reducing cardiovascular morbidity or mortality is unclear. We compared the effects of diltiazem with that of diuretics, beta-blockers, or both on cardiovascular (...) morbidity and mortality in hypertensive patients.In a prospective, randomised, open, blinded endpoint study, we enrolled 10,881 patients, aged 50-74 years, at health centres in Norway and Sweden, who had diastolic blood pressure of 100 mm Hg or more. We randomly assigned patients diltiazem, or diuretics, beta-blockers, or both. The combined primary endpoint was fatal and non-fatal stroke, myocardial infarction, and other cardiovascular death. Analysis was done by intention to treat.Systolic

2000 Lancet

16. Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm

Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm Shapira O M, Alkon J D, Macron D S F, Keaney J F, Vita J A, Aldea G S, Shemin R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study focused on the use of two conduit vasodilators in the prevention of arterial conduit spasm after coronary bypass grafting (CABG). Patients received a 24-hour intravenous infusion of either nitroglycerin (0.1 microgram.kg-1.min-1) or diltiazem (0.1 mg/kg during 20 minutes and then 0.1 mg.kg-1.min-1), followed by 6 months

2000 NHS Economic Evaluation Database.

17. Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery

Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 NHS Economic Evaluation Database.

18. Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery

Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 NHS Economic Evaluation Database.

19. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. (PubMed)

Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. The effect of dihydropyridines in patients with unstable angina is discouraging. To find out the effect of the non-dihydropyridine-like calcium-channel blocker diltiazem, a randomised, double-blind trial was conducted comparing diltiazem with glyceryl trinitrate, both given intravenously, in 129 patients with unstable angina. The endpoints were refractory angina or myocardial (...) infarction, individually and as a composite endpoint. Refractory angina alone or together with myocardial infarction occurred significantly less commonly in the diltiazem group. While patients were on the trial drugs the numbers with refractory angina were 6 (10%) in the diltiazem group versus 17 (28%) in the glyceryl trinitrate group (relative risk 0.36, p = 0.02), and the numbers with refractory angina and myocardial infarction were 9 (15%) versus 23 (38%) (relative risk 0.40, p = 0.007). Over 48 h

1996 Lancet

20. Spotlight article: a preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. (Schroeder JS, Gao SZ, Alderman EL, et al. N Engl J Med 1992; 328:164-70.). (PubMed)

Spotlight article: a preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. (Schroeder JS, Gao SZ, Alderman EL, et al. N Engl J Med 1992; 328:164-70.). 8226013 1993 12 16 2013 11 21 0147-9563 22 5 1993 Sep-Oct Heart & lung : the journal of critical care Heart Lung Spotlight article: a preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. (Schroeder JS, Gao SZ, Alderman EL, et al. N Engl J (...) Med 1992; 328:164-70.). 464-7 Scordo K A KA Cardiology Center of Cinncinnati, OH 45242. eng Clinical Trial Journal Article Randomized Controlled Trial United States Heart Lung 0330057 0147-9563 EE92BBP03H Diltiazem AIM IM Coronary Disease prevention & control Diltiazem therapeutic use Heart Transplantation Humans 1993 9 1 1993 9 1 0 1 1993 9 1 0 0 ppublish 8226013

1993 Heart & lung : the journal of critical care